Launched in 2016, Israel Haifa based Paragate Medical is an innovative device company, aiming to revolutionize the heart failure epidemic management by shifting the weight of chronic disease treatment out of the hospital towards home-based care.
Our Mission is to reduce fluid overload in Chronic Heart and Kidney Failure patients, the greatest burden on the healthcare system.
CEO and managing partner of NGT3 Incubator. Former CEO and director of Beta-O2 Technologies (a biomedical company which developed proprietary Implantable bio-artificial pancreas) for a period of 8 years, brought the company to one of the world leaders positioning in the area.
Served as CEO of the Technion Entrepreneurial Incubator (TEIC) for a period of 11 years. Led the establishment and investment in more than 40 companies, such as Prolor Biotech (Opko), Mazor Robotics (Medtronic), Corindus (Siemens), ReWalk (NASDAQ: RWLK) and many others. Gained a wide range of experience in identifying new technologies and in establishing, directing, and creating value for technology-based start-up companies. M.Sc. in material engineering, B.Sc. in physics, and MBA, all from the Technion, Israel Institute of Technology.
Over 20 years’ experience in the MedDev industry – working with start-ups, large companies and global corporations. He fulfilled roles in R&D, IP, Quality, Clinical and Regulatory Affairs, leading multiple projects from early stages through clinical trials.
He is involved in over 30 patents and applications in medical imaging, detectors, neural stimulation and invasive cardiology. Former senior director R&D in Edwards life science, leading cutting-edge development of structural heart devices (SapienIII). Prior to that served as VP R&D and Application in Brainsgate, were he led negotiation and execution of IDE trial of over 800 patients, and department manager of system engineering at GE. Hernan brings strong skillset for taking medical devices from pipeline development through clinical trials and regulation.
Nizar served as the Managing Partner and Chief Financial Officer for New Generation Technology incubator (NGT), where he supported over ten portfolio companies.
He managed the finances of these companies with strong leadership, closely following the budget, making sure the companies receive their full government money, and ensuring they set goals and achieve what they should (and when) with their funds. He has also taken an active role with follow-on funding and handling complex investment transactions. Previously, Nizar was the Chairman and Director of Positive Care. He holds Certified Public Accountant license with Greenberg & Shneor and holds a M.B.A. from Tel Aviv University.
Over thirteen years of experience in cardiovascular and neuromodulation medical devices field in various R&D, engineering and management positions, from which seven with Enopace Biomedical – pioneering the conceptualization and development of intravascular neurostimulation device for treatment of heart failure.
Involved with companies in the fields of stroke treatment, renal denervation, peripheral interventional, acute kidney injury and ventilation monitoring. B.Sc., M.Sc. in Biomedical Engineering, Technion-IIT, Haifa, Israel Graduate project spun-off as startup (Pneumedicare) for ventilation monitoring. Conducted research in Cardiac Resynchronization Therapy, awarding him as young investigator award of the Israeli Society for Heart Research (ISHR).
Dr. Yair Feld is a practicing cardiologist in Rambam Healthcare Campus. Yair has over 20 years of experience in managing life science companies and leading innovative research and development projects.
He founded several medical technology companies among which Nephera Ltd., Corassist Cardiovascular and Proarc. He has 10 years of experience in leading innovative research and development projects. Yair received his MD and PhD (physiology and biophysics) from the Technion-Israel Institute of Technology, as well as a BA is Physics from the University of Tel-Aviv.
Piotr Ponikowski MD, PhD, FESC, is Head of the Department of Heart Diseases, Wroclaw Medical University and Head of the Cardiology Department at the Center for Heart Diseases at 4th Military Hospital, Wroclaw, Poland.
Former president of the European Heart Failure Association and Chair of the European Guidelines for HF management. His research interests mainly include heart failure (HF), coronary artery disease and cardiac arrhythmias. He has been involved in numerous research projects, such as the benefits of physical rehabilitation in patients with chronic HF, assessment of metabolic derangements in HF (with special interest in iron deficiency), evaluation of reflex control in the cardiorespiratory system in order to optimize assessment and management of patients with HF. He has been involved in numerous clinical trials as main investigator, member of international steering committees, endpoint committees and advisory boards.
Dr Costanzo Maria Rosa Costanzo, MD, FESC, FACC, FHSA, is a Worldwide Leading Researcher in Ultrafiltration Therapy. She is Medical Director of the Heart Failure Program with Midwest Heart Specialists, and Medical Director of the Edward Center for Advanced Heart Failure in Naperville, Illinois.
Dr Costanzo was Director of the Loyola University Chicago Heart Failure and Cardiac Transplant Program between 1988 and 1994, and of the Rush Heart Failure and Cardiac Transplant Program between 1994 and 2001. She is a Member of the Research Committee of the Heart Failure Society of America (HFSA). Between 1995 and 2000, Dr Costanzo was Editor in Chief of the Journal of Heart and Lung Transplantation. She has published more than 150 peer-reviewed manuscripts and is the author of numerous review papers, monographs, and book chapters.
Uri Elkayam, MD FHSA, is a Professor of Medicine and a Professor of Obstetrics and Gynecology at the University of Southern California. He is a nationally and internationally known expert in heart failure and heart disease in pregnancy.
Dr Elkayam is a past member of the executive council of the Heart Failure Society of America and the chairman of its corporate affairs committee. He is a present or past editorial board member of the Journal of the American College of Cardiology, American Journal of Cardiology, Journal of Cardiac Failure, Heart Failure, Heart Failure Reviews, Journal of Preventive Cardiology and Cardiology in Review.